Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;102(6):1228-1237.
doi: 10.1016/j.kint.2022.07.012.

Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Paul Martin  1 , Ahmed A Awan  2 , Marina C Berenguer  3 , Annette Bruchfeld  4 , Fabrizio Fabrizi  5 , David S Goldberg  6 , Jidong Jia  7 , Nassim Kamar  8 , Rosmawati Mohamed  9 , Mário Guimarães Pessôa  10 , Stanislas Pol  11 , Meghan E Sise  12 , Ethan M Balk  13 , Craig E Gordon  14 , Gaelen Adam  13 , Michael Cheung  15 , Amy Earley  15 , Michel Jadoul  16
Affiliations
Free article
Review

Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Paul Martin et al. Kidney Int. 2022 Dec.
Free article

Abstract

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.

Keywords: KDIGO; chronic kidney disease; cryoglobulinemia; dialysis; direct-acting antivirals; glomerular diseases; guideline; hemodialysis; hepatitis C virus; infection control; kidney transplantation; liver testing; nosocomial transmission; screening; systematic review.

PubMed Disclaimer